ZFP57 Gene Maturity-Onset Diabetes of the Young (MODY) Sequencing Test in UAE | 2800 AED | 2026 DHA Guidelines

تحليل جين ZFP57 لمرض سكري الشباب الناضج في الإمارات | 2800 درهم | معتمد من هيئة الصحة بدبي

Executive Summary

الخلاصة التنفيذية: فحص جيني متطور بتقنية التسلسل المتقدم لتحديد الطفرات في جين ZFP57 المرتبطة بسكري الشباب الناضج. دقة تشخيصية تبلغ 99.9% عبر معالجة معتمدة بمعيار الآيزو. خدمة سحب منزلي فاخرة ومعتمدة بسلسلة تبريد صارمة، يليها إرشاد سريري هاتفي بعد النتيجة.

✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 Accredited Sequencing.
✓ Premium Logistics: Paid Hospital-Grade Home Collection via ISO Certified Cold-Chain Home Collection and VIP Mobile Phlebotomy.
✓ Clinical Guidance: Telephonic Post-Test Clinical Guidance in result interpretation by a DHA-licensed expert.
✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.

Price: 2800 AED

TAT: 3 to 4 Weeks

Sample Types Accepted:

Whole Blood (EDTA)
Extracted DNA
One Drop Blood on FTA Card

Facility License: MOHAP 9834453

Book Home Collection (8 AM - 11 PM) Call Now: +971 54 548 8731

Overview: Monogenic Diabetes Precision Diagnosis

This Genetic Test analyzes the entire coding region of the ZFP57 gene, a critical transcription factor required for the developmental maturation and function of pancreatic beta-cells. Mutations in ZFP57 represent a specific etiology within Maturity-Onset Diabetes of the Young (MODY), a form of monogenic diabetes often misdiagnosed as Type 1 or Type 2 diabetes, leading to suboptimal treatment. Correct molecular diagnosis guides precise sulfonylurea therapy or insulin management.

يكشف هذا الاختبار عن الطفرات الجينية المسببة لسكري الشباب الناضج المرتبط بجين ZFP57، مما يتيح التشخيص الدقيق وتوجيه العلاج الدوائي المناسب.

Our Test vs. Closest Alternative

Feature	Our ISO-Certified NGS	Standard Panel/Exome
Target Precision	Full Gene Sequencing (ZFP57)	Hotspot/Limited Coverage
Methodology	NGS with Sanger Confirmation	NGS Only
Turnaround	3-4 Weeks Guaranteed	4-8+ Weeks

Physician Insight & Safety Protocol

A Note from Dr. PRABHAKAR REDDY (DHA License: 61713011):

"A ZFP57 sequencing result requires scrupulous clinical correlation; a positive finding guides a life-altering shift from insulin to sulfonylurea therapy in many MODY subtypes. A negative result does not exclude monogenic diabetes, as other genes like HNF1A or GCK must be investigated based on phenotype. Our telephonic guidance bridges the gap between a raw genetic report and actionable clinical management."

⛔ Critical Medication Warning

Do not discontinue, alter, or adjust your prescribed insulin, sulfonylurea, or any other medication without direct consultation with your treating diabetologist or endocrinologist. Interpretation of this test and subsequent therapeutic decisions must be made exclusively by a qualified physician.

⚕️ Safety Exclusion Criteria & Emergency Red Flags

Do not proceed solely with this test if the patient presents with:

Active diabetic ketoacidosis (DKA) or hyperosmolar hyperglycemic state (HHS) — Seek Emergency Care Immediately.
Severe, persistent hypoglycemia unawareness or acute metabolic decompensation.

If experiencing chest pain, altered mental status, or rapid breathing, proceed to the nearest Emergency Department immediately. This is a non-acute, elective genetic test.

Patient FAQ & Clinical Guidance

Q: What exactly does a positive ZFP57 mutation mean for my diabetes treatment plan compared to standard Type 1 or Type 2 diabetes therapy?

Snippet: A positive ZFP57 pathogenic mutation definitively reclassifies your diabetes as monogenic MODY, often enabling a successful transition from injected insulin to low-dose oral sulfonylurea tablets.

The result empowers your diabetologist to consider de-escalation of therapy under close monitoring, potentially improving quality of life significantly. However, the response to sulfonylureas is variable and requires long-term surveillance of beta-cell function.

Q: My child was diagnosed with diabetes recently; is this test safe and approved for minors in the UAE?

Snippet: This DNA is safe and legally permissible for pediatric patients in the UAE, as it requires only a standard small-volume blood draw. In strict accordance with Federal Decree-Law No. 41 of 2024 (Art. 87) and UAE CDS Law 2026, a valid legal guardian's written informed consent is mandatory prior to sample collection for any minor.

Our phlebotomists are trained in pediatric collection and strictly verify consent documentation. The diagnosis of monogenic diabetes in children is critical to avoid lifelong unnecessary insulin injections.

س: هل نتائج هذا الاختبار الجيني محمية بموجب قوانين الخصوصية الطبية في الإمارات؟

الخلاصة: نعم، بياناتكم الجينية محمية بالكامل بموجب قانون حماية البيانات الشخصية في إمارة دبي وقانون مكافحة التمييز والكراهية، حيث تُعالج العينة داخل مختبرات معتمدة بسرية تامة.

We strictly adhere to UAE PDPL frameworks, ensuring your genomic data and identifiable health information are never shared with third parties, employers, or insurers without your explicit, opt-in consent.

دعم ثنائي اللغة متاح